Last reviewed · How we verify
NCT03533998
Biomarkers in Prostate Cancer Treated With SRP Following Failure of FAT
trial in Prostatic Neoplasms in 30 participants. Status unknown.
30 September 2018
Quick facts
| Lead sponsor | Institut Mutualiste Montsouris |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 31 May 2018 |
| Primary completion | 30 September 2018 |
| Estimated completion | 30 September 2018 |
| Sites | 1 location across France |
Conditions studied
- Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Sponsor
Institut Mutualiste Montsouris — full company profile →
Who can join
Adults 50 to 75, male only, with Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The ability of genomic biomarkers to Measuring tumour aggressiveness, and facilitate the selection of therapies in patients who had salvage radical prostatectomy after focal therapy and predict the risk of biochemical recurrence BCR after focal therapy or RP.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03533998
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostatic Neoplasms
Currently open trials in the same condition.
- NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
- NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
- NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
- NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
- NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting
Other Institut Mutualiste Montsouris trials
Trials by the same sponsor.
- NCT06982625 — Supra Inguinal Fascia Iliaca Block as Rescue Analgesia Following Total Hip Arthroplasty · NA · recruiting
- NCT06007274 — Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors · completed
- NCT06020651 — Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside · NA · completed
- NCT05799898 — Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors · recruiting
- NCT05301218 — CAlcified Lesion Intervention Planning Steered by OCT. · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03533998 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Mutualiste Montsouris
- Last refreshed: 23 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03533998.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing